THREE PHASE 1/2, OPEN‐LABEL STUDIES OF CEREBLON E3 LIGASE MODULATOR (CELMOD)‐BASED REGIMENS IN NEWLY DIAGNOSED (ND) OR RELAPSED/REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL)
Hematological Oncology | June 17, 2021 | Volume: 39 | Issue: S2 | Pages: No page available
10.1002/hon.173_2880